Miriam Champer1, Yongmei Huang1, June Y Hou2, Ana I Tergas3, William M Burke2, Grace Clarke Hillyer4, Cande V Ananth5, Alfred I Neugut3, Dawn L Hershman3, Jason D Wright6. 1. Columbia University College of Physicians and Surgeons, United States. 2. Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, United States; New York Presbyterian Hospital, United States. 3. Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, United States; New York Presbyterian Hospital, United States; Mailman School of Public Health, Columbia University, United States. 4. Mailman School of Public Health, Columbia University, United States. 5. Columbia University College of Physicians and Surgeons, United States; Mailman School of Public Health, Columbia University, United States. 6. Columbia University College of Physicians and Surgeons, United States; Herbert Irving Comprehensive Cancer Center, United States; New York Presbyterian Hospital, United States. Electronic address: jw2459@columbia.edu.
Abstract
OBJECTIVE: Treatment selection for recurrent ovarian cancer is typically based on the duration of time between the completion of adjuvant, platinum-based therapy and the time of recurrence, the platinum free interval (PFI). We examined the use of, and outcomes associated with platinum-based chemotherapy based on the PFI in women with recurrent ovarian cancer. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to identify women aged >65years with epithelial ovarian cancer who underwent surgery and platinum-based chemotherapy and who developed a recurrence >3months after the completion of adjuvant therapy. Patients were stratified by PFI into 3 groups: PFI <6months, PFI 7-12months, and PFI >12months. Multivariable models were used to examine predictors of use of platinum-based therapy and survival for each group. RESULTS: A total of 2369 patients were identified. In women with a PFI of ≤6months, treatment consisted of platinum-based combination therapy in 28.2%, single agent platinum in 5.2% and non-platinum therapy in 66.6%. Corresponding rates of these treatments among women with a PFI of 7-12months were 39.7%, 12.4% and 47.9%, respectively; the rates were 57.6%, 13.2% and 29.3% in those with a PFI of >12months, respectively. Median survival was 13, 18, and 27months for patients with a PFI of ≤6months, 7-12months, and >12months, respectively (P<0.0001). For all three groups, platinum combination therapy was associated with decreased risk of death compared to non‑platinum based therapy. CONCLUSION: Platinum free interval is a strong predictor of survival in elderly women with recurrent ovarian cancer. There is widespread variation in treatment selection for women with recurrent ovarian cancer with many women receiving non-guideline based regimens.
OBJECTIVE: Treatment selection for recurrent ovarian cancer is typically based on the duration of time between the completion of adjuvant, platinum-based therapy and the time of recurrence, the platinum free interval (PFI). We examined the use of, and outcomes associated with platinum-based chemotherapy based on the PFI in women with recurrent ovarian cancer. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to identify women aged >65years with epithelial ovarian cancer who underwent surgery and platinum-based chemotherapy and who developed a recurrence >3months after the completion of adjuvant therapy. Patients were stratified by PFI into 3 groups: PFI <6months, PFI 7-12months, and PFI >12months. Multivariable models were used to examine predictors of use of platinum-based therapy and survival for each group. RESULTS: A total of 2369 patients were identified. In women with a PFI of ≤6months, treatment consisted of platinum-based combination therapy in 28.2%, single agent platinum in 5.2% and non-platinum therapy in 66.6%. Corresponding rates of these treatments among women with a PFI of 7-12months were 39.7%, 12.4% and 47.9%, respectively; the rates were 57.6%, 13.2% and 29.3% in those with a PFI of >12months, respectively. Median survival was 13, 18, and 27months for patients with a PFI of ≤6months, 7-12months, and >12months, respectively (P<0.0001). For all three groups, platinum combination therapy was associated with decreased risk of death compared to non‑platinum based therapy. CONCLUSION:Platinum free interval is a strong predictor of survival in elderly women with recurrent ovarian cancer. There is widespread variation in treatment selection for women with recurrent ovarian cancer with many women receiving non-guideline based regimens.
Authors: Maurie Markman; John Blessing; Stephen C Rubin; Joseph Connor; Parviz Hanjani; Steven Waggoner Journal: Gynecol Oncol Date: 2005-12-02 Impact factor: 5.482
Authors: A Lortholary; R Largillier; B Weber; L Gladieff; J Alexandre; X Durando; B Slama; J Dauba; D Paraiso; E Pujade-Lauraine Journal: Ann Oncol Date: 2011-05-11 Impact factor: 32.976
Authors: Jason D Wright; William M Burke; Elizabeth T Wilde; Sharyn N Lewin; Abigail S Charles; Jin Hee Kim; Noah Goldman; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Jason D Wright; Ana I Tergas; June Y Hou; William M Burke; Yongmei Huang; Jim C Hu; Grace Clarke Hillyer; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Obstet Gynecol Date: 2016-03 Impact factor: 7.661
Authors: Helen E Dinkelspiel; Ana I Tergas; Lilli A Zimmerman; William M Burke; June Y Hou; Ling Chen; Grace Hillyer; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2015-02-20 Impact factor: 5.482
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: Xianglin L Du; Shenying Fang; Sally W Vernon; Hashem El-Serag; Y Tina Shih; Jessica Davila; Monica L Rasmus Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Marieke J Krimphove; Karl H Tully; David F Friedlander; Maya Marchese; Praful Ravi; Stuart R Lipsitz; Kerry L Kilbridge; Adam S Kibel; Luis A Kluth; Patrick A Ott; Toni K Choueiri; Quoc-Dien Trinh Journal: J Immunother Cancer Date: 2019-11-07 Impact factor: 13.751